Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M E Trautmann

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
Diabetic Medicine : a Journal of the British Diabetic Association|February 24, 2006
Exenatide: effect of injection time on postprandial glucose in patients with Type 2 diabetesH Linnebjerg, P A Kothare, Z Skrivanek, et al.
Hormone and Metabolic Research. Supplement Series|January 1, 1993
Receptor scintigraphy with 111In-pentetreotide for endocrine gastroenteropancreatic tumorsK Joseph, J Stapp, J Reinecke, et al.
Deutsche Medizinische Wochenschrift (1946)|June 26, 1992
[Receptor scintigraphy in endocrine gastrointestinal and pancreatic tumors]K Joseph, J Stapp, J Reinecke, et al.
Hormone and Metabolic Research. Supplement Series|January 1, 1993
The role of somatostatin analogs in the treatment of endocrine gastrointestinal tumorsM E Trautmann, C Neuhaus, H Lenze, et al.
Nuklearmedizin. Nuclear Medicine|December 1, 1993
[Receptor scintigraphy using 111In-pentetreotide in endocrine gastroenteropancreatic tumors]K Joseph, J Stapp, J Reinecke, et al.
Diabetes, Obesity & Metabolism|January 13, 2012
Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatmentMark S Fineman, K F Mace, M Diamant, et al.
Gut|March 1, 1996
Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumoursR Arnold, M E Trautmann, W Creutzfeldt, et al.
Diabetes, Obesity & Metabolism|June 17, 2006
Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetesL Blonde, E J Klein, J Han, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Diabetic Medicine : a Journal of the British Diabetic Association|February 24, 2006
Exenatide: effect of injection time on postprandial glucose in patients with Type 2 diabetesH Linnebjerg, P A Kothare, Z Skrivanek, et al.
Hormone and Metabolic Research. Supplement Series|January 1, 1993
Receptor scintigraphy with 111In-pentetreotide for endocrine gastroenteropancreatic tumorsK Joseph, J Stapp, J Reinecke, et al.
Deutsche Medizinische Wochenschrift (1946)|June 26, 1992
[Receptor scintigraphy in endocrine gastrointestinal and pancreatic tumors]K Joseph, J Stapp, J Reinecke, et al.
Hormone and Metabolic Research. Supplement Series|January 1, 1993
The role of somatostatin analogs in the treatment of endocrine gastrointestinal tumorsM E Trautmann, C Neuhaus, H Lenze, et al.
Nuklearmedizin. Nuclear Medicine|December 1, 1993
[Receptor scintigraphy using 111In-pentetreotide in endocrine gastroenteropancreatic tumors]K Joseph, J Stapp, J Reinecke, et al.
Diabetes, Obesity & Metabolism|January 13, 2012
Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatmentMark S Fineman, K F Mace, M Diamant, et al.
Gut|March 1, 1996
Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumoursR Arnold, M E Trautmann, W Creutzfeldt, et al.
Diabetes, Obesity & Metabolism|June 17, 2006
Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetesL Blonde, E J Klein, J Han, et al.
Pageof 4